This article is more than 5 years old. Information may no longer be current.

John Snisarenko named Shire’s group vice president, head of ophthalmics

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Shire has named John Snisarenko as its new group vice president and head of ophthalmics in the United States, according to company correspondence.

Snisarenko, who most recently served as vice president of sales and marketing for Genentech’s rheumatology franchise, has 30 years of experience in the pharmaceutical, biotech and medical device industries. He has also held positions at Novartis Pharma Canada, Ciba Vision, Novadaq Technologies, Alcon Canada and Allergan Canada.

John Snisarenko

“I am joining Shire on the eve of the first anniversary of the ophthalmics franchise first marketed product, Xiidra, whose market performance has exceeded expectations,” Snisarenko said in the correspondence. “I look forward to continuing to build on the successes of the ophthalmics franchise, including advancing our pipeline and footprint in the eye care space.”

Snisarenko is replacing Robert Dempsey, who has taken a leadership role in Shire’s global business as vice president and head of global ophthalmics.